Hans Gelderblom, Victoria Wang, Mark Doherty, Ana Sebio, Silvia Stacchiotti, Breelyn A. Wilky, Jean-Yves Blay, Andrew Scott Brohl, Claudia Maria Valverde Morales, Peter Reichardt, Javier Martin-Broto, Elizabeth J. Davis, Jacco J. De Haan, Brianne O'Neill, Erin Babcock, Josep Garcia, Lane Senne, Dale Shepard, Sant P. Chawla, Robin Lewis Jones. "The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.11504